David O Holtz , M.D.

GENERAL

Specialty:	Gynecologic Oncology (Board Certified in 2008) - Accepting New Patients

Age: 44      Gender: M
Years in practice: 8
Main Line HealthCare Physician

Medical School:
Jefferson Medical College

Internship:
Thomas Jefferson University Hospital

Residency:
Thomas Jefferson University Hospital

Fellowship:
Hospital of the University of Pennsylvania

Primary Affiliation:  Lankenau Medical Center

* Members of the Main Line Health medical staff are affiliated with Bryn Mawr Hospital, Lankenau Medical Center, Paoli Hospital and Riddle Hospital.

Clinical/Dept Titles:
Main Line Health System Division Chief - Gynecologic Oncology

---

PRACTICE

Practice Name:
Main Line Gynecologic Oncology

Locations:

Lankenau Medical Ctr, MOB East Suite 661 100 East Lancaster Avenue Wynnewood, PA  19096 TEL: 610.649.8085 FAX: 610.649.8984

Hours: Weekdays

Paoli Hospital, MOB 3 Suite 231 255 West Lancaster Ave Paoli, PA  19301 TEL: 610.649.8085 FAX: 610.649.8984

Access Information:  Public Transportation,Handicap Access Hours: Weekdays

Areas of Clinical Interest
Minimally Invasive Laparoscopic Surgery
Laparoscopic & Robotic Treatment of Complex Endometriosis, Endometrial, Cervical, & Ovarian Cancers
Ovarian and Endometrial Cancer
Vaginal and Vulvar Cancer
Abnormal Pap Smears
Chemotherapy in the Treatment of GYN Cancers
Cancer Research

Statement of Practice Philosophy

Provide care for patients with complex gynecologic problems, including women with gynecologic malignancies or complex surgical problems. Care also provided for patients diagnosed with precancerous lesions of the cervix, as well as evaluation of Pap smear abnormalities.

Patient Population

• Adult
• Adolescent
• Geriatric
• Medicare
• HMO
• PPO
• Self-Pay

---

PUBLICATIONS & CITATIONS

Recent Clinical Studies Published

PUBLISHED WORKS

Dunton CJ, Dooley M, Holtz DO. Early detection of cervical cancer by human papilomavirus DNA testing: Case Reports. J Low Genit Tract Dis 10:256-7, 2006.

Dumoff KL, Chu CS, Harris EE, Holtz D, Xu X, Zhang PJ, Acs G. Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation. Mod Pathol 19:708-16, 2006.

Holtz DO, Dunton CJ. Traditional management of invasive cervical cancer.Obstetrics & Gynecology Clinics of North America: 29(4):645-57,2002.

Holtz DO, Ramondetta LM, Burke TW, Palazzo JP, Dunton CJ, Atkinson EN, Broaddus RR. PTEN expression in tamoxifen-associated endometrial cancers.Anticancer Research22(5):2945-8, 2002.

Goldberg J, Holtz DO, Hyslop T, Tolosa JE.Has the use of routine episiotomy decreased?..Examination of episiotomy rates from 1983 to 2000.Obstetrics & Gynecology 99(3): 395-400, 2002.

Holtz DO, Holland G, Ropp BG, Dunton CJ. Hysteroscopic resection of uterine lipoleiomyoma: Case study and literature review.Journal of Lower Genital Tract Disease October, 2000.

Goldberg J, Holtz DO, Hyslop T, Tolosa JE. Has the use of routine episiotomy decreased? Examination of episiotomy rates from 1983 to 2000.Int J Gyn Obstet 200383(s3):108.

Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ, Holtz DO, Jenkins A,Na H, Zhang L, Wagner DS, Katsaros D, Caroll R, Coukos G. Tumor-infiltrating dendritic cell precursors recruited by beta-defensin contribute to vasculogenesis under the influence of VEGF.Published Online: 29 August 2004.

PRESENTATIONS

Holtz, D, Zhang L, Coureges C, Mohamed A, Benencia F, Conejo-Garcia J, Rubin SC, Coukos G. Treatment with vascular endothelial growth factor receptor-2 inhibitor SU5416 in combination with cisplatin or paclitaxel effects tumor growth in mouse ovarian cardinoma model. (Focused Plenary Abstract 18)
Society of Gynecologic Oncolgists Annual Meeting 2004

Holtz D, Zhang L, Coureges C, Mohamed A, Benencia F, Conejo-Garcia J, Rubin SC, Coukos G. Treatment with vascular endothelial growth factor receptor-2 inhibitor SU5416 in combination with cisplatin or paclitaxel effects tumor growth in mouse ovarian cardinoma model. (Focused Plenary Abstract 18)
GlaxoSmithKline National Gynecologic Oncolgy Fellows' Forum 2004

Holtz D, Coureges C, Mohamed A, Benencia F, Rubin SC, Coukos G. Tyrosine kinase inhibitor SU5416 suppresses tumor growth in a syngeneic mouse model of ovarian cardinoma overexpressing VEGF-164. (Abstract 212)
Society of Gynecologic Oncologists Annual Meeting 2003

Holtz D, Coureges C, Mohamed A, Benencia F, Rubin SC, Coukos G. Tyrosine kinase inhibitor SU5416 suppresses tumor growth in a syngeneic mouse model of ovarian cardinoma overexpressing VEGF-164.
GlaxoSmithKline National Gynecologic Oncology Fellows' Forum 2003

RESEARCH GRANTS

Principal Investigator - A Prospective, Randomized, Controlled Evaluation of Fibrin Sealant 2 (FS2) as an Adjunct to Hemostatis During Retroperitoneal or Intra-abdominal Surgery. Ethicon Inc., 2006.

Principal Investigator - Detecting Integrated Human Papillomavirus DNA in Cervial Cells. One Cell Systems, 2005.

Recent Honors, Awards, Citations

2012 - TOP DOCTOR - Gynecologic Oncology
Philadelphia Magazine

2000 - Felix Rutledge Fellow in Gynecologic Oncology
M.D. Anderson Cancer Center

Personal Quote

Visit the Women's Health Source website for an article I wrote on Ovarian Cysts and Masses in Menopause.

Current Memberships and Activities

• American Association of Gynecologic Laparoscopists
• American Society for Colposcopy and Cervical Pathology
• Society of Gynecologic Oncologists
• Mid-Atlantic Gynecologic Oncology Society
• American College of Obstetrics & Gynecology
• Pennsylvania Medical Society